BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Qin P, Zhang M, Liu X, Dong Z. Immunogenomic Landscape Analysis of Prognostic Immune-Related Genes in Hepatocellular Carcinoma. J Healthc Eng 2021;2021:3761858. [PMID: 34745496 DOI: 10.1155/2021/3761858] [Reference Citation Analysis]
2 Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. J Oncol. 2019;2019:4304817. [PMID: 31182960 DOI: 10.1155/2019/4304817] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
3 Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Biomed Res Int 2020;2020:9037217. [PMID: 32090113 DOI: 10.1155/2020/9037217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
4 Nie Y, Jiang MC, Liu C, Liu Q, Zhu X. CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates. Front Oncol 2021;11:637023. [PMID: 33869023 DOI: 10.3389/fonc.2021.637023] [Reference Citation Analysis]
5 Gottstein B, Soboslay P, Ortona E, Wang J, Siracusano A, Vuitton DΑ. Immunology of Alveolar and Cystic Echinococcosis (AE and CE). Adv Parasitol 2017;96:1-54. [PMID: 28212788 DOI: 10.1016/bs.apar.2016.09.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
6 Meng Q, Duan X, Yang Q, Xue D, Liu Z, Li Y, Jin Q, Guo F, Jia S, Wang Z, Yan W, Chang X, Sun P. SLAMF6/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization. Oncol Lett 2022;23:83. [PMID: 35126725 DOI: 10.3892/ol.2022.13203] [Reference Citation Analysis]
7 Zhang Q, Yuan XF, Lu Y, Li ZZ, Bao SQ, Zhang XL, Yang YY, Fan DM, Zhang YZ, Wu CX, Guo HX, Zhang YJ, Ye Z, Xiong DS. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells. Int J Cancer 2017;141:1445-57. [PMID: 28643325 DOI: 10.1002/ijc.30846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2019; 25(27): 3649-3663 [PMID: 31367163 DOI: 10.3748/wjg.v25.i27.3649] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
9 Lai KP, Cheung A, Ho CH, Tam NY, Li JW, Lin X, Chan TF, Lee NP, Li R. Transcriptomic analysis reveals the oncogenic role of S6K1 in hepatocellular carcinoma. J Cancer 2020;11:2645-55. [PMID: 32201535 DOI: 10.7150/jca.40726] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018;20:322-9. [PMID: 28801777 DOI: 10.1007/s12094-017-1720-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
11 Li K, Lan Y, Wang J, Liu L. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles. Tumour Biol 2017;39:1010428317692229. [PMID: 28347250 DOI: 10.1177/1010428317692229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
12 Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel) 2017;8:E76. [PMID: 28218682 DOI: 10.3390/genes8020076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dasgupta A, Dey D, Ghosh D, Lai TK, Bhuvanesh N, Dolui S, Velayutham R, Acharya K. Astrakurkurone, a sesquiterpenoid from wild edible mushroom, targets liver cancer cells by modulating Bcl-2 family proteins. IUBMB Life 2019;71:992-1002. [PMID: 30977280 DOI: 10.1002/iub.2047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95 [DOI: 10.13105/wjma.v7.i3.80] [Reference Citation Analysis]
15 Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, Liu Q, Bai J, Liu H, Zheng J, Yao H. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018;19:475-483. [PMID: 29400599 DOI: 10.1080/15384047.2018.1433501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
16 Yang E, Li X, Jin N. The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment. Cancer Cell Int 2016;16:80. [PMID: 27752239 DOI: 10.1186/s12935-016-0351-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019;9:19. [PMID: 30719425 DOI: 10.3389/fonc.2019.00019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
18 Xie Y, Xiang Y, Sheng J, Zhang D, Yao X, Yang Y, Zhang X. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. J Immunol Res 2018;2018:8740976. [PMID: 29785403 DOI: 10.1155/2018/8740976] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]